文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

黑色素瘤脑转移患者的联合免疫治疗:一项多中心国际研究

Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
PubMed 文献 · Eur J Cancer · 2024-01-19

该多中心回顾性研究纳入376例接受伊匹木单抗联合纳武利尤单抗(COMBO)治疗的黑色素瘤脑转移患者,评估其疗效与安全性。中位随访30个月,总体中位OS为21.3个月;初治、无症状、未用激素患者OS未达到。BRAF/MEK抑制剂进展后接受COMBO者1年PFS为15.7%。

要点

  • 初治、无症状、未用激素的黑色素瘤脑转移患者接受COMBO可获得显著长期生存。
  • 无症状患者中,立体定向放射外科联合COMBO较单用COMBO延长生存(p=0.013)。
  • BRAF/MEK抑制剂进展后接受COMBO的患者PFS和OS较差,1年PFS为15.7%。

核心结论

  • 初治、无症状、未用激素的黑色素瘤脑转移患者以及接受立体定向放射外科联合COMBO的患者可获得显著的长期生存。
  • BRAF/MEK抑制剂进展后接受COMBO的患者PFS和OS较差。

研究设计与样本

  • 多中心国际回顾性研究,连续纳入376例接受COMBO治疗的黑色素瘤脑转移患者。
  • 262例接受COMBO作为一线治疗,114例作为后续治疗。
  • 独立验证队列纳入51例患者,证实了上述发现。

关键数值与推荐

  • 初治、基线未用激素患者的中位OS尚未达到。
  • BRAF/MEK抑制剂治疗后接受COMBO的患者1年PFS为15.7%。
  • 地塞米松剂量(< vs ≥ 4 mg/天)无预后价值。
  • 无症状患者中,立体定向放射外科联合COMBO vs 单用COMBO延长生存(p=0.013)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ipilimumab plus nivolumab (COMBO) is the standard treatment in asymptomatic patients with melanoma brain metastases (MBM). We report a retrospective study aiming to assess the outcome of patients with MBM treated with COMBO outside clinical trials. METHODS: Consecutive patients treated with COMBO have been included. Demographics, steroid treatment, Central Nervous System (CNS)-related symptoms, BRAF status, radiotherapy or surgery, response rate (RR), progression-free (PFS) and overall survival (OS) have been analyzed. RESULTS: 376 patients were included: 262 received COMBO as first-line and 114 as a subsequent line of therapy, respectively. In multivariate analysis, Eastern Cooperative Oncology Group (ECOG) (≥1 vs 0) [HR 1.97 (1.46-2.66)], extracerebral metastases [HR 1.92 (1.09-3.40)], steroid use at the start of COMBO [HR 1.59 (1.08-2.38)], CNS-related symptoms [HR 1.59 (1.08-2.34)], SRS (Stereotactic radiosurgery) [HR 0.63 (0.45-0.88)] and surgery [HR 0.63 (0.43-0.91)] were associated with OS. At a median follow-up of 30 months, the median OS (mOS) in the overall population was 21.3 months (18.1-24.5), whilst OS was not yet reached in treatment-naive patients, steroid-free at baseline. In patients receiving COMBO after BRAF/MEK inhibitors(i) PFS at 1-year was 15.7%. The dose of steroids (dexamethasone < vs ≥ 4 mg/day) was not prognostic. SRS alongside COMBO vs COMBO alone in asymptomatic patients prolonged survival. (p = 0.013). Toxicities were consistent with previous studies. An independent validation cohort (n = 51) confirmed the findings. CONCLUSIONS: Our results demonstrate remarkable long-term survival in treatment-naïve, asymptomatic, steroid-free patients, as well as in those receiving SRS plus COMBO. PFS and OS were poor in patients receiving COMBO after progressing to BRAF/MEKi.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mandalà M, Lorigan P, Sergi MC, et al. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study. Eur J Cancer. 2024. PMID: 38266540. doi:10.1016/j.ejca.2024.113542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。